Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum~* Inoperable metastatic disease~* Immunohistochemical evidence of epidermal growth factor receptor expression in tumor tissue~* Presence of at least 1 bi-dimensionally measurable index lesion~Exclusion Criteria:~* Previous irinotecan-based chemotherapy~* Previous chemotherapy for colorectal cancer except adjuvant treatment if terminated more than 6 months before the start of study treatment~* Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of study treatment~* Brain metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab Plus FOLFIRI (Type: EXPERIMENTAL): None
- FOLFIRI Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).